查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1967652

狂犬病獸用疫苗市場－全球產業規模、佔有率、趨勢、機會、預測：按應用、分銷管道、地區和競爭格局分類，2021-2031年

Rabies Veterinary Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球獸用狂犬病疫苗市場預計將從 2025 年的 6.1234 億美元成長到 2031 年的 8.2435 億美元，複合年成長率為 5.08%。

這些疫苗採用減毒活病毒疫苗、去活化疫苗或重組病毒株，作為生物免疫劑，可在家畜、伴侶動物和野生動物體內產生主動免疫力。推動疫苗市場成長的關鍵因素包括：旨在預防通用感染疾病傳播的「同一健康」策略的日益普及，以及寵物人性化趨勢的增強，這促使人們定期在預防性獸醫護理方面投入資金。根據美國寵物用品協會 (APPA) 的報告，2023 年美國寵物產業的總支出達到 1,470 億美元，這清楚地表明，飼主在動物福利方面的大量支出正在支撐疫苗需求。

市場概覽
預測期 2027-2031
市場規模：2025年 6.1234億美元
市場規模：2031年 8.2435億美元
複合年成長率：2026-2031年 5.08%
成長最快的細分市場 野生動物
最大的市場 北美洲

儘管有這些成長要素，開發中國家市場在分銷和倉儲物流方面仍面臨嚴峻挑戰。雖然維持持續的低溫運輸至關重要，但在非洲和亞洲等高負擔地區，基礎設施的限制常常與此相衝突，導致疫苗劣化和取得受限。這些物流問題會嚴重阻礙有效的群體免疫接種工作，並限制市場滲透率。

市場促進因素

全球寵物擁有率的上升以及人們對動物日益人性化的認知正在從根本上改變市場模式。隨著飼主越來越將寵物視為家庭成員，對預防性生技藥品和高品質獸醫服務的需求也不斷成長。這種文化轉變促使人們更加嚴格地遵守疫苗接種計劃，以確保伴侶動物的健康和長壽，從而導致新興市場和已開發國家的年度疫苗接種劑量均顯著增加。根據歐洲寵物產業協會（FEDIAF）於2024年6月發布的《2024年度報告》，歐洲寵物產業服務超過3.5億隻寵物，顯示預防性產品市場潛力巨大。此外，碩騰公司（Zoetis）報告稱，其2024年伴侶動物產品收入達55.8億美元，這充分體現了支撐市場持續成長的巨大經濟價值。

第二個關鍵驅動力是基於「同一健康」理念的全球根除策略的擴展，該策略強調動物健康與人類健康之間的聯繫，致力於根除犬源性狂犬病。國際組織和各國政府正在加強強制免疫接種，並增加對大規模免疫宣傳活動的資金投入，以切斷病毒傳播源頭。這些努力在通用感染疾病風險嚴重的地區至關重要，需要儲備大量疫苗以用於公共衛生措施。例如，狂犬病防治組織Mission Rabies在2024年11月報告稱，其團隊在柬埔寨開展的為期兩週的密集宣傳活動中，成功為229,488隻犬隻接種了疫苗，這充分說明了這種協調行動的規模。這清楚地表明，有針對性的根除計劃如何直接推動狂犬病疫苗的大規模分發和使用。

市場挑戰

發展中國家的物流配送和倉儲系統是全球獸用狂犬病疫苗市場成長的主要障礙。理論上，非洲和亞洲的狂犬病流行地區對疫苗的需求最高，但對不間斷低溫運輸的嚴格要求卻成為瓶頸，阻礙了生產商有效地服務這些地區。在交通基礎設施落後、電力供應不穩定的地區，疫苗往往難以維持在所需的溫度範圍內，導致經銷商遭受重大浪費和經濟損失。因此，市場相關人員被迫將供應鏈限制在都市區，使得最需要疫苗的廣大農村地區難以取得疫苗。

由於無法保證疫苗的有效性，大規模疫苗宣傳活動的發展受到限制，進而阻礙了疫苗的大規模消費，直接導致市場規模萎縮。疫苗短缺與疾病負擔沉重之間的差距，意味著該行業商業性機會的重大損失。根據世界衛生組織（世衛組織）2024年的數據，高達95%的人類狂犬病死亡病例發生在亞洲和非洲，這一統計數據凸顯了這些地區缺乏有效的獸醫應對方案，以及疫苗銷售的巨大潛力尚未得到充分開發，因為這些地區的基礎設施嚴重不足。

市場趨勢

目前，市場正經歷從傳統去活化病毒製劑向mRNA疫苗和重組顆粒疫苗等先進平台技術的明顯轉型，這些技術具有更高的免疫抗原性和安全性。這項技術進步使得開發無佐劑製劑成為可能，透過精準的抗原編碼誘導更強的免疫反應，同時消除注射部位肉瘤的風險。為了支持這項商業性轉變，默克動物保健公司於2024年6月發布新聞稿，宣布其Nobivac NXT產品組合在加拿大成功上市，並推出了一種新型狂犬病疫苗。這是首個採用RNA顆粒技術的伴侶動物狂犬病疫苗系列。

同時，旨在控制野生動物族群中病毒攜帶者並建立免疫屏障以防止感染傳播給家畜的口服狂犬病疫苗（ORV）策略的應用正在顯著擴大。各國政府正在增加對大規模地面和空中投放狂犬病誘餌的資金投入，這些誘餌使用穩定的疫苗結構和新型引誘劑，即使在地形複雜的情況下，也能有效針對狐狸和浣熊等難以捕捉的媒介動物。例如，美國農業部（USDA）在2024年7月報告稱，聯邦機構已在東北部八個州分發了約330萬個口服狂犬病誘餌（ONRAB），以評估群體免疫和分發方法的有效性，這便體現了這些根除工作的規模。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球獸用狂犬疫苗市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依用途（伴侶動物、家畜、野生動物）
    • 分銷管道（零售、電子商務、醫​​院/診所藥房）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美獸用狂犬疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲獸用狂犬疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區獸用狂犬疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲獸用狂犬疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲獸用狂犬疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球獸用狂犬疫苗市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Zoetis Inc.
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • Virbac SA
  • Indian Immunologicals Ltd.
  • Ceva Sante Animale SA
  • Sanofi SA
  • Elanco Animal Health Inc.
  • BroadChem Philippines Biopharma Corporation
  • BiogenesisBago SA

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23983

The Global Rabies Veterinary Vaccines Market is projected to expand from USD 612.34 Million in 2025 to USD 824.35 Million by 2031, registering a CAGR of 5.08%. These vaccines, which utilize live-attenuated, inactivated, or recombinant viral strains, function as biological immunizing agents to generate active immunity in livestock, companion animals, and wildlife. Growth is largely propelled by the increasing adoption of "One Health" strategies aimed at stopping zoonotic transmission, alongside the rising trend of pet humanization that encourages regular spending on preventive veterinary health. As reported by the American Pet Products Association, total U.S. pet industry expenditures reached $147 billion in 2023, highlighting the significant financial investment owners make in animal welfare that sustains vaccine demand.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 612.34 Million
Market Size 2031USD 824.35 Million
CAGR 2026-20315.08%
Fastest Growing SegmentWildlife Animals
Largest MarketNorth America

Despite these growth factors, the market faces substantial hurdles related to distribution and storage logistics within developing countries. The strict necessity for maintaining a continuous cold chain frequently conflicts with infrastructure limitations in high-burden areas across Africa and Asia, resulting in vaccine spoilage and restricted access. These logistical failures can severely hamper effective mass immunization initiatives and limit market penetration.

Market Driver

The rising trends of global pet ownership and animal humanization are fundamentally altering the market landscape, as owners increasingly regard pets as essential family members, thereby boosting the demand for preventive biologicals and premium veterinary care. This cultural evolution fosters stricter adherence to vaccination schedules to guarantee the health and longevity of companion animals, drastically increasing the annual volume of doses administered in both emerging and developed economies. According to the 'Annual Report 2024' by FEDIAF in June 2024, the European pet industry caters to over 350 million pets, highlighting a massive addressable market for immunization products. Furthermore, Zoetis reported generating $5.58 billion in revenue from companion animal products in 2024, demonstrating the immense financial value supporting ongoing market growth.

A second pivotal driver is the expansion of 'One Health' global eradication strategies, which underscore the connection between animal and human health in the effort to eliminate dog-mediated rabies. International organizations and governments are increasingly enforcing vaccination mandates and financing mass immunization drives to cut off viral transmission at the source. These efforts are crucial in high-burden regions with acute zoonotic risks, requiring significant vaccine stockpiles for public health measures. Highlighting the magnitude of these coordinated actions, Mission Rabies reported in November 2024 that their teams successfully vaccinated 229,488 dogs in Cambodia during a two-week intensive campaign, showing how targeted eradication schemes directly drive the mass distribution and consumption of rabies vaccines.

Market Challenge

Distribution and storage logistics in developing nations constitute a significant obstacle to the growth of the global rabies veterinary vaccines market. Although the theoretical demand for immunization is highest in endemic areas within Africa and Asia, the stringent need for an unbroken cold chain creates a bottleneck that hinders manufacturers from effectively serving these regions. In locations suffering from poor transport infrastructure and unreliable electricity, keeping vaccines within the required temperature range is often unfeasible, leading to substantial spoilage rates and financial losses for distributors. As a result, market players are often forced to restrict supply chains to urban hubs, leaving vast rural populations-who need the product most-largely without access.

This inability to ensure product viability directly reduces market volume by limiting mass immunization campaigns that would otherwise generate large-scale vaccine consumption. The gap between low vaccine accessibility and high disease burden represents a major missed commercial opportunity for the industry. According to the World Health Organization in 2024, up to 95% of human rabies deaths occurred in Asia and Africa, a statistic that highlights the critical absence of effective veterinary control programs and the massive unrealized potential for vaccine sales in these markets lacking adequate infrastructure.

Market Trends

The market is undergoing a distinct transition toward advanced platform technologies, moving away from conventional inactivated virus formulations in favor of mRNA and recombinant particle vaccines that provide enhanced immunogenicity and safety. This technological progression enables the creation of adjuvant-free formulas that remove the risk of injection-site sarcomas while eliciting a stronger immune response through precise antigen coding. Confirming this commercial shift, Merck Animal Health announced in a June 2024 press release regarding 'New Rabies Vaccine Availability in Canada' that it had successfully launched the Nobivac NXT portfolio, marking the first veterinary rabies vaccine line for companion animals to employ RNA-particle technology.

Simultaneously, there is significant growth in the application of Oral Rabies Vaccination (ORV) strategies designed to control viral reservoirs in wildlife populations, thereby establishing immunological barriers against spillover into domestic animals. Governments are increasingly funding extensive ground and aerial baiting initiatives that use stable vaccine constructs and novel attractants to target elusive vector species, such as foxes and raccoons, in difficult terrains. To illustrate the scope of these abatement efforts, the U.S. Department of Agriculture (USDA) reported in July 2024 that federal agencies managed the distribution of roughly 3.3 million ONRAB oral vaccine baits across eight northeastern states to assess herd immunity efficacy and distribution methods.

Key Market Players

  • Zoetis Inc.
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • Virbac S.A.
  • Indian Immunologicals Ltd.
  • Ceva Sante Animale S.A.
  • Sanofi S.A.
  • Elanco Animal Health Inc.
  • BroadChem Philippines Biopharma Corporation
  • BiogenesisBago S.A.

Report Scope

In this report, the Global Rabies Veterinary Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rabies Veterinary Vaccines Market, By Application

  • Companion Animals
  • Livestock Animals
  • Wildlife Animals

Rabies Veterinary Vaccines Market, By Distribution Channel

  • Retail
  • E-Commerce
  • Hospital/Clinic Pharmacies

Rabies Veterinary Vaccines Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rabies Veterinary Vaccines Market.

Available Customizations:

Global Rabies Veterinary Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rabies Veterinary Vaccines Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Companion Animals, Livestock Animals, Wildlife Animals)
    • 5.2.2. By Distribution Channel (Retail, E-Commerce, Hospital/Clinic Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Rabies Veterinary Vaccines Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Rabies Veterinary Vaccines Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Rabies Veterinary Vaccines Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Rabies Veterinary Vaccines Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Distribution Channel

7. Europe Rabies Veterinary Vaccines Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Rabies Veterinary Vaccines Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Rabies Veterinary Vaccines Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Rabies Veterinary Vaccines Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Rabies Veterinary Vaccines Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Rabies Veterinary Vaccines Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Rabies Veterinary Vaccines Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Rabies Veterinary Vaccines Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Rabies Veterinary Vaccines Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Rabies Veterinary Vaccines Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Rabies Veterinary Vaccines Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Rabies Veterinary Vaccines Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Rabies Veterinary Vaccines Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Rabies Veterinary Vaccines Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Rabies Veterinary Vaccines Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Rabies Veterinary Vaccines Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Distribution Channel

10. South America Rabies Veterinary Vaccines Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Rabies Veterinary Vaccines Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Rabies Veterinary Vaccines Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Rabies Veterinary Vaccines Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Rabies Veterinary Vaccines Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Zoetis Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Boehringer Ingelheim International GmbH
  • 15.3. Merck & Co., Inc.
  • 15.4. Virbac S.A.
  • 15.5. Indian Immunologicals Ltd.
  • 15.6. Ceva Sante Animale S.A.
  • 15.7. Sanofi S.A.
  • 15.8. Elanco Animal Health Inc.
  • 15.9. BroadChem Philippines Biopharma Corporation
  • 15.10. BiogenesisBago S.A.

16. Strategic Recommendations

17. About Us & Disclaimer